AKESO (09926.HK): Completes 20m-share placing, nets HK$1.94bn
On 16 October 2026, AKESO (09926.HK) placed 20,000,000 new shares at HK$97.76 each to at least six placees, raising net proceeds of HK$1,940.98 million.
Key Highlights:
- The placing completed on 16 October 2026, with 20,000,000 shares placed at HK$97.76 each to not fewer than six placees.
- Net proceeds of about HK$1,940.98 million will be used as previously disclosed.
NewTimeSpace News: On 16 October 2026, Akeso, Inc. (09926.HK) said the conditions of its 14 October 2026 placing agreement for new shares under a general mandate were fulfilled and the placing completed on 16 October 2026. 20,000,000 shares were placed at HK$97.76 each to not fewer than six placees, about 2.13% of the enlarged issued share capital.
After deducting commission, related expenses and professional fees, net proceeds were about HK$1,940.98 million, to be used as previously disclosed; the placees and their ultimate beneficial owners are third-party investors independent of the Company and its connected persons. Following the placing, total issued shares rose from 921,143,176 to 941,143,176.
Tags：
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit
- AKESO (09926.HK): NMPA Approves Third Indication of Ivonescimab (PD-1/VEGF) for First-Line Treatment of Advanced Squamous NSCLC
- Akeso(09926.HK): Grant of Share Options and Restricted Share Units
- AKESO(09926.HK): Qiyoukang® (Gumokimab) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis
